Related Experiment Video
Updated: Aug 5, 2026
10:38
Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
Published on: December 16, 2022
In Vitro Antitumor Properties of Simvastatin-Loaded SBA-16 Mesoporous Nanoparticles Using Two- and Three-Dimensional
Akram J Kadhim1, Ibrahim Tawfiq2, Mohamed El-Tanani3
1Pharmacological and Diagnostic Research Center (PDRC), Faculty of Pharmacy, Al-Ahliyya Amman University, P.O. Box 183, Amman 19328, Jordan.
Pharmaceutics
|July 28, 2026
Summary
Simvastatin encapsulated in SBA-16 nanoparticles significantly enhances its anticancer effect against colorectal cancer (CRC) cells. This novel drug delivery system improves simvastatin
Area of Science:
- Nanotechnology
- Pharmacology
- Oncology
Background:
- Colorectal cancer (CRC) poses a significant global health challenge, with treatment limited by poor drug selectivity and resistance.
- Simvastatin, a statin drug, has shown potential anticancer properties but faces challenges in delivery and efficacy.
- Developing advanced drug delivery systems is crucial to overcome therapeutic limitations in CRC treatment.
Purpose of the Study:
- To investigate the enhanced anticancer efficacy of simvastatin when encapsulated in mesoporous SBA-16 nanoparticles (NPs) against colorectal cancer cells.
- To compare the performance of simvastatin-loaded SBA-16 NPs with free simvastatin in both 2D and 3D cell culture models.
- To evaluate the anti-inflammatory effects of the simvastatin-loaded NPs by measuring interleukin-6 (IL-6) levels.
Main Methods:
- Simvastatin was loaded into mesoporous SBA-16 nanoparticles, achieving high drug-loading efficiency and rapid release kinetics.
- HT-29 colorectal cancer cells were cultured in 2D monolayer and 3D spheroid models.
- Cell viability, proliferation, and cytotoxicity were assessed using MTT and clonogenic assays.
- Interleukin-6 (IL-6) levels were quantified using ELISA to evaluate anti-inflammatory activity.
Main Results:
- Simvastatin-loaded SBA-16 NPs demonstrated a 6.29-fold increase in cytotoxic potency compared to free simvastatin, significantly reducing the IC50 value.
- The nanoparticle formulation effectively inhibited colony formation and suppressed IL-6 secretion, suggesting modulation of inflammatory pathways.
- In 3D spheroid models, the simvastatin-loaded NPs exhibited superior dose-dependent inhibition compared to the free drug.
Conclusions:
- Mesoporous SBA-16 nanocarriers substantially enhance simvastatin's anticancer efficacy against colorectal cancer cells.
- The improved efficacy is attributed to enhanced drug solubilization and rapid release kinetics, potentially aided by improved cellular uptake.
- Further in vivo studies are warranted to confirm the clinical applicability of this nanocarrier system for CRC treatment.
